Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Harding

Showing results (821-830 of 945) with videos related to

Pageof 95
Sort By:
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
High-Affinity, Structure-Validated and Selective Macrocyclic Peptide Tools for Chemical Biology Studies of HuntingtinEsther Wolf, Rebeka Fanti, Tatsuya Ikenoue, et al.
Cochlear Implants International|December 25, 2016
United Kingdom national paediatric bilateral project: Demographics and results of localization and speech perception testingH E Cullington, D Bele, J C Brinton, et al.
Journal of Geophysical Research. Space Physics|October 15, 2021
First results from the retrieved column O/N<sub>2</sub> ratio from the Ionospheric Connection Explorer (ICON): Evidence of the impacts of nonmigrating tidesScott L England, R R Meier, Harald U Frey, et al.
The Oncologist|May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain MetastasesJames J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Cochlear Implants International|January 19, 2017
United Kingdom national paediatric bilateral project: Results of professional rating scales and parent questionnairesH E Cullington, D Bele, J C Brinton, et al.
Annals of Surgical Oncology|July 23, 2024
Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer DatabaseLauren E Schleimer, Hannah L Kalvin, Ryan J Ellis, et al.
Cancer|August 24, 2017
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinomaMaeve A Lowery, Kenneth H Yu, David Paul Kelsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
High-affinity, structure-validated and selective macrocyclic peptide tools for chemical biology studies of HuntingtinRebeka Fanti, Esther Wolf, Tatsuya Ikenoue, et al.
Pageof 95

Showing results (821-830 of 945) with videos related to

Sort By:
Pageof 95
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
High-Affinity, Structure-Validated and Selective Macrocyclic Peptide Tools for Chemical Biology Studies of HuntingtinEsther Wolf, Rebeka Fanti, Tatsuya Ikenoue, et al.
Cochlear Implants International|December 25, 2016
United Kingdom national paediatric bilateral project: Demographics and results of localization and speech perception testingH E Cullington, D Bele, J C Brinton, et al.
Journal of Geophysical Research. Space Physics|October 15, 2021
First results from the retrieved column O/N<sub>2</sub> ratio from the Ionospheric Connection Explorer (ICON): Evidence of the impacts of nonmigrating tidesScott L England, R R Meier, Harald U Frey, et al.
The Oncologist|May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain MetastasesJames J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Cochlear Implants International|January 19, 2017
United Kingdom national paediatric bilateral project: Results of professional rating scales and parent questionnairesH E Cullington, D Bele, J C Brinton, et al.
Annals of Surgical Oncology|July 23, 2024
Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer DatabaseLauren E Schleimer, Hannah L Kalvin, Ryan J Ellis, et al.
Cancer|August 24, 2017
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinomaMaeve A Lowery, Kenneth H Yu, David Paul Kelsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
High-affinity, structure-validated and selective macrocyclic peptide tools for chemical biology studies of HuntingtinRebeka Fanti, Esther Wolf, Tatsuya Ikenoue, et al.
Pageof 95